৳ 1/unit
Pack: ৳ 1
৳ 1/unit
Pack: ৳ 1
At a glance
Ledipasvir + Sofosbuvir is a combination of two antiviral medicines used for the treatment of chronic hepatitis C virus (HCV) infection. It inhibits viral replication and helps resolve the infection.
Indications
- Chronic hepatitis C virus (HCV) infection - genotypes 1, 4, 5, or 6
Pharmacology
Ledipasvir inhibits the HCV NS5A protein which is important for viral replication, assembly and secretion. Sofosbuvir's triphosphate metabolite is incorporated into the HCV RNA chain by HCV RNA polymerase, causing chain termination.
Dosage
Adult Dose (Oral):
- One tablet (Ledipasvir 90 mg + Sofosbuvir 400 mg) once daily
- With or without food
- Duration: Treatment-naive with or without cirrhosis: 12 weeks; Treatment-experienced without cirrhosis: 12 weeks; Treatment-experienced with cirrhosis: 24 weeks
Hepatic Impairment: Mild-severe: No dosage adjustment required
Side effects
Common Side Effects:
- Fatigue
- Headache
- Nausea
- Diarrhea
- Insomnia
Use in pregnancy
Use in Pregnancy: Ledipasvir + Sofosbuvir is generally considered safe during pregnancy (FDA Category B). Animal studies have shown low or no adverse effects to the developing baby.
Pregnancy Category: B — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Caution when driving or activities requiring concentration (may cause dizziness and blurred vision)
- Serious bradycardia with Amiodarone - not recommended
- Monitor liver function and viral load regularly
- Limit or avoid alcohol
- Do not stop suddenly
Overdose effects
No specific overdose information available; symptomatic and supportive measures should be employed.
Storage conditions
Keep out of reach of children; store in a cool and dry place, protected from light.